Keyphrases
Castration-resistant Prostate Cancer
100%
Clinical Considerations
100%
Androgen Receptor Splice Variant 7
100%
Androgen Receptor
33%
Splice Variant
33%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
Prostate Cancer
16%
Clinical Data
16%
Ligand-independent
16%
Biospecimens
16%
Prostate Cancer Cells
16%
Enzalutamide
16%
Androgen Deprivation Therapy
16%
Acquired Resistance
16%
Abiraterone
16%
Predictive Biomarker
16%
Androgen Receptor Antagonist
16%
Tumoral
16%
Adaptive Response
16%
Preclinical Data
16%
Constitutively Active
16%
Treatment Selection
16%
Potential Therapeutic Strategies
16%
Primary Resistance
16%
Taxane Chemotherapy
16%
Medicine and Dentistry
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Biological Marker
25%
Prostate Cancer
25%
Chemotherapy
12%
Cancer Cell
12%
Androgen Deprivation Therapy
12%
Adaptive Response
12%
Abiraterone
12%
Androgen
12%
Enzalutamide
12%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Prostate Cancer
25%
Biological Marker
25%
Androgen
25%
Chemotherapy
12%
Enzalutamide
12%
Abiraterone
12%
Taxane
12%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
Cancer Cell
12%
Adaptive Response
12%
Enzalutamide
12%